

S53

EFFECT OF EPIGENETIC INHIBITORS ON LUNG FIBROBLAST PHENOTYPE CHANGE IN IDIOPATHIC PULMONARY FIBROSIS

A Pasini, OJ Brand, G Jenkins, AJ Knox, L Pang. *Division of Respiratory Medicine – University of Nottingham, Nottingham, UK*

10.1136/thoraxjnl-2016-209333.59

Introduction and objectives Idiopathic Pulmonary Fibrosis (IPF) is a fatal interstitial lung disease with unknown aetiology. Lung myofibroblasts (activated fibroblasts) are the major effector cells in the pathogenesis of IPF. Transforming growth factor- β (TGF- β 1) is a potent activator of fibroblasts. Lack of effective treatment options necessitates novel therapeutic approaches. Epigenetic drugs, by inhibiting chromatin modifying enzymes involved in gene expression control, represent promising agents capable of modulating the cellular phenotype.

We previously demonstrated that the cyclooxygenase-2 (COX-2) gene is epigenetically silenced in lung fibroblasts from IPF patients (F-IPF)¹ and epigenetic inhibitors can restore COX-2 expression. However, whether epigenetic inhibitors can alter fibroblast phenotype remains unknown. This study aimed to investigate the effect of four different epigenetic enzyme inhibitors on fibroblast phenotype change in IPF.

Methods F-IPF and fibroblasts from non-fibrotic lung (F-NL) treated with TGF- β 1 were cultured to test the effects of the epigenetic inhibitors BIX01294 (BIX, G9a histone methyltransferase inhibitor), 3-deazaneplanocin A (DZNep, EZH2 histone methyltransferase inhibitor), SAHA (histone deacetylases inhibitor) and Decitabine (DAC, DNA demethylating agent), in comparison with the COX-2 products prostaglandin E2 (PGE2). The expression of COX-2 and myofibroblast markers collagen 1 (COL1) and α -smooth muscle actin (α -SMA) was assessed. The COX-2 DNA promoter methylation level was analysed by bisulfite sequencing.

Results TGF- β 1 induced a myofibroblast phenotype in F-NL characterised by COL1 and α -SMA upregulation and COX-2 downregulation, similar to F-IPF. PGE2 and SAHA were able to maintain/restore COX-2 expression in TGF- β 1-induced myofibroblasts and F-IPF. DAC demonstrated similar effect in TGF- β 1 treated F-NL only. SAHA also reduced COL1 and α -SMA expression. But DZNep and BIX showed no effect. No differences in the COX-2 promoter methylation was detected between F-NL and F-IPF.

Conclusions Among the epigenetic inhibitors tested, SAHA shows a promising antifibrotic effect by inhibiting fibroblast activation and the underlying molecular mechanisms are currently under investigation.

REFERENCE

- 1 Coward WR, Feghali-Bostwick CA, Jenkins G, *et al.* A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. *FASEB J* 2014;**28**(7):3183–96.

Lungs and Inflation


S54

CPAP REDUCES EXACERBATIONS IN TRACHEOBRONCHOMALACIA

M Demirbag, G Tavernier, T Morris, K Hince, C Ustabasi, D Jones, S Fowler. *University Hospital South Manchester, Manchester, UK*

10.1136/thoraxjnl-2016-209333.60

Overview Tracheobronchomalacia (TBM) is increasingly recognised as a significant diagnosis in patients diagnosed with “severe asthma”. Continuous Positive Airway Pressure (CPAP) is used as first line treatment to stent the airway in TBM patients in order to clear mucus and prevent irritation, inflammation and bacterial overgrowth thereby reducing the number of exacerbations experienced by patients. However, there is currently no published data which evaluates whether this intervention has an impact on outcomes in. This study describes a cohort of patients referred to a regional centre for severe asthma patients, who were



Abstract S54 Figure 1